Success Story: Advancing Targeted Drug Delivery Research for Neurodegenerative Diseases: NIW Approval Secured for a Pharmaceutical Sciences Researcher from Nepal
Client’s Testimonial:
"I am incredibly thankful for all the support throughout the application process.”
On May 27th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Graduate Research Assistant
Country of Origin: Nepal
State of Residence at the Time of Filing: North Dakota
Approval Notice Date: May 27th, 2026
Processing Time: 1 year, 5 months (Premium Processing Requested)
Case Summary:
The client’s work focuses on a major challenge in pharmaceutical sciences, namely, how to deliver small-molecule drugs and biologics more precisely to improve therapeutic outcomes while reducing unwanted side effects. His proposed endeavor centered on targeted drug delivery approaches using nanocarriers such as lipid nanoparticles, polymeric nanoparticles, and exosomes, with a particular focus on developing therapeutics for neurodegenerative diseases. At the time of filing, he was conducting pharmaceutical sciences research at a U.S. research university, where his work involved brain-targeted delivery systems, nanocarriers, biologics, and therapeutic strategies for conditions such as Alzheimer’s disease.
Research with National Importance
The client’s research addresses the need for more effective drug delivery systems for difficult-to-treat conditions. His work examines how nanocarriers can help deliver small-molecule drugs, nucleic acids, antibodies, and other biologics to targeted sites in the body, including the brain. By studying lipid nanoparticles, polymeric nanoparticles, non-viral gene delivery, and blood-brain barrier models, his work contributes to the development of more precise therapies for neurodegenerative disorders and other serious diseases.
Academic Contributions and Recognition
At the time of filing, the client’s record included 6 peer-reviewed journal articles, 4 first-authored conference abstracts, 2 book chapters, 587 citations, and at least 7 peer reviews for authoritative journals in his field. His publication record included work on nanotherapeutics for neurodegenerative disorders, blood-brain barrier models, transdermal protein delivery, functionalized nanoparticles, and brain-targeted delivery systems.
Several of his papers were cited at especially high rates in Pharmacology and Toxicology for their publication years, including 1 paper ranked within the top 0.01%, 1 paper ranked within the top 1%, and 1 paper ranked within the top 10%. These citation rankings helped show that independent researchers had relied on his work at a notable rate.
Recognition from Experts
Recommendation letters submitted with the petition emphasized the client’s expertise in pharmaceutical sciences, targeted drug delivery, nanocarrier systems, and neurodegenerative disease research. Experts highlighted that his work supports the development of more precise therapeutic strategies for conditions where effective delivery to the brain remains a major scientific challenge.
One expert stated:
“[Client]’s skill set is remarkable, with far-reaching implications for the investigation and treatment of neurodegenerative disorders. His contributions benefit not only the scientific community but also the healthcare system and society at large.”
This endorsement helped show that the client’s work has practical relevance beyond publication alone. Together with his citation record, peer review service, highly ranked publication venues, NIH-supported research, and documented reliance on his findings by independent researchers, the expert support strengthened the petition’s argument that his contributions are significant to pharmaceutical sciences and healthcare innovation.
NIW Approval and Outlook
The I-140 NIW petition was filed on December 27th, 2024, later upgraded to Premium Processing, and approved on May 27th, 2026. The approval recognized the national importance of the client’s work in pharmaceutical sciences, particularly his research on targeted drug delivery, nanocarriers, biologics, and therapeutic development for neurodegenerative diseases.
This result supports the client’s continued work in advancing drug delivery research and developing more precise therapeutic approaches. We congratulate him on this approval and wish him continued success in contributing to pharmaceutical sciences and healthcare innovation in the United States.